We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Recommends Kadcyla, Kyprolis and Rejects Besponsa Coverage
NICE Recommends Kadcyla, Kyprolis and Rejects Besponsa Coverage
The U.K. is planning to move Roche’s Kadcyla (trastuzumab emtansine) into the NHS’s routine funding programs later this summer, following guidance from the National Institute for Health and Care Excellence and an agreement from Roche to lower the cost of the breast cancer treatment.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor